Treatment of recurrent ovarian cancer: increasing options--"recurrent" results
RF Ozols
JCO Jun 1 1997: 2177–2180. [PDF]
Kids, cancer, and the Joe Camel connection
HK Koh
JCO Jun 1 1997: 2181–2182. [PDF]
	Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
	W ten Bokkel Huinink, M Gore, J Carmichael, A Gordon, J Malfetano, I Hudson, C Broom, C Scarabelli, N Davidson, M Spanczynski, G Bolis, H Malmstrom, R Coleman, SC Fields, and JF Heron
	JCO Jun 1 1997: 2183–2193. [Abstract] [PDF]
	Tobacco use among pediatric cancer patients: recommendations for developing clinical smoking interventions
	VL Tyc, MM Hudson, P Hinds, V Elliott, and MY Kibby
	JCO Jun 1 1997: 2194–2204. [Abstract] [PDF]
	Late mortality of long-term survivors of childhood cancer
	MM Hudson, D Jones, J Boyett, GB Sharp, and CH Pui
	JCO Jun 1 1997: 2205–2213. [Abstract] [PDF]
	Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study
	FM Uckun, PS Gaynon, MG Sensel, J Nachman, ME Trigg, PG Steinherz, R Hutchinson, BC Bostrom, HN Sather, and GH Reaman
	JCO Jun 1 1997: 2214–2221. [Abstract] [PDF]
	Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group
	J Nachman, HN Sather, PS Gaynon, JN Lukens, L Wolff, and ME Trigg
	JCO Jun 1 1997: 2222–2230. [Abstract] [PDF]
	Philadelphia chromosome in relapsed childhood acute lymphoblastic leukemia: a matched-pair analysis. Berlin-Frankfurt-Munster Study Group
	B Beyermann, HP Adams, and G Henze
	JCO Jun 1 1997: 2231–2237. [Abstract] [PDF]
	Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation--a report from the Societe Francaise de Greffe de Moelle
	G Michel, G Socie, F Gebhard, F Bernaudin, I Thuret, JP Vannier, F Demeocq, G Leverger, JL Pico, H Rubie, F Mechinaud, J Reiffers, N Gratecos, X Troussard, JP Jouet, G Simonin, E Gluckman, and D Maraninchi
	JCO Jun 1 1997: 2238–2246. [Abstract] [PDF]
	Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group
	G Schellong, M Riepenhausen, U Creutzig, J Ritter, J Harbott, G Mann, and H Gadner
	JCO Jun 1 1997: 2247–2253. [Abstract] [PDF]
	Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults
	EJ Bow, R Loewen, MS Cheang, TB Shore, M Rubinger, and B Schacter
	JCO Jun 1 1997: 2254–2261. [Abstract] [PDF]
	Expression of c-mpl mRNA, the receptor for thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with poor response to intensive chemotherapy
	M Wetzler, MR Baer, SH Bernstein, L Blumenson, C Stewart, M Barcos, K Mrozek, AW Block, GP Herzig, and CD Bloomfield
	JCO Jun 1 1997: 2262–2268. [Abstract] [PDF]
	Acyclovir prophylaxis and fever during remission-induction therapy of patients with acute myeloid leukemia: a randomized, double-blind, placebo-controlled trial
	OJ Bergmann, SC Mogensen, S Ellermann-Eriksen, and J Ellegaard
	JCO Jun 1 1997: 2269–2274. [Abstract] [PDF]
	Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease
	M Loeffler, V Diehl, M Pfreundschuh, U Ruhl, D Hasenclever, H Nisters-Backes, M Sieber, H Tesch, J Franklin, W Geilen, H Bartels, C Cartoni, G Dolken, J Enzian, R Fuchs, W Gassmann, H Gerhartz, U Hagen-Aukamp, E Hiller, H Hinkelbein, W Hinterberger, H Kirchner, P Koch, B Kruger, and EW Schwarze
	JCO Jun 1 1997: 2275–2287. [Abstract] [PDF]
	Engraftment and molecular monitoring of CD34+ peripheral-blood stem- cell transplants for follicular lymphoma: a pilot study
	IG McQuaker, AP Haynes, S Anderson, C Stainer, RG Owen, GJ Morgan, M Lumley, D Milligan, J Fletcher, EM Bessell, JM Davis, and NH Russell
	JCO Jun 1 1997: 2288–2295. [Abstract] [PDF]
	Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma
	SM Ansell, TM Habermann, PJ Kurtin, TE Witzig, MG Chen, CY Li, DJ Inwards, and JP Colgan
	JCO Jun 1 1997: 2296–2301. [Abstract] [PDF]
	Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group
	KI Pritchard, AH Paterson, S Fine, NA Paul, B Zee, LE Shepherd, H Abu-Zahra, J Ragaz, M Knowling, MN Levine, S Verma, D Perrault, PL Walde, VH Bramwell, M Poljicak, N Boyd, D Warr, BD Norris, D Bowman, GR Armitage, H Weizel, and RA Buckman
	JCO Jun 1 1997: 2302–2311. [Abstract] [PDF]
	Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results
	AM Gianni, S Siena, M Bregni, M Di Nicola, S Orefice, F Cusumano, B Salvadori, A Luini, M Greco, R Zucali, F Rilke, M Zambetti, P Valagussa, and G Bonadonna
	JCO Jun 1 1997: 2312–2321. [Abstract] [PDF]
	Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease
	DW Chan, RA Beveridge, H Muss, HA Fritsche, G Hortobagyi, R Theriault, D Kiang, BJ Kennedy, and M Evelegh
	JCO Jun 1 1997: 2322–2328. [Abstract] [PDF]
	Race and clinical outcome in breast cancer in a series with long-term follow-up evaluation
	R Heimann, D Ferguson, C Powers, D Suri, RR Weichselbaum, and S Hellman
	JCO Jun 1 1997: 2329–2337. [Abstract] [PDF]
	Age-related patterns of care: evidence against ageism in the treatment of early-stage breast cancer
	E Guadagnoli, C Shapiro, JH Gurwitz, RA Silliman, JC Weeks, C Borbas, and SB Soumerai
	JCO Jun 1 1997: 2338–2344. [Abstract] [PDF]
	Sentinel lymphadenectomy in breast cancer
	AE Giuliano, RC Jones, M Brennan, and R Statman
	JCO Jun 1 1997: 2345–2350. [Abstract] [PDF]
	Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684
	BE Hillner, JM Kirkwood, MB Atkins, ER Johnson, and TJ Smith
	JCO Jun 1 1997: 2351–2358. [Abstract] [PDF]
	Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases
	D Berd, HC Maguire, Jr, LM Schuchter, R Hamilton, WW Hauck, T Sato, and MJ Mastrangelo
	JCO Jun 1 1997: 2359–2370. [Abstract] [PDF]
	Treatment of Kaposi's sarcoma after solid organ transplantation
	FA Shepherd, E Maher, C Cardella, E Cole, P Greig, JA Wade, and G Levy
	JCO Jun 1 1997: 2371–2377. [Abstract] [PDF]
	High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence
	SR Patel, S Vadhan-Raj, N Papadopolous, C Plager, MA Burgess, C Hays, and RS Benjamin
	JCO Jun 1 1997: 2378–2384. [Abstract] [PDF]
	Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide
	JD Hainsworth, JB Erland, LA Kalman, MT Schreeder, and FA Greco
	JCO Jun 1 1997: 2385–2393. [Abstract] [PDF]
	Definitive radiotherapy for T3 squamous cell carcinoma of the glottic larynx
	WM Mendenhall, JT Parsons, AA Mancuso, FJ Pameijer, SP Stringer, and NJ Cassisi
	JCO Jun 1 1997: 2394–2402. [Abstract] [PDF]
	Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: a randomized trial
	HA Burris, 3rd, MJ Moore, J Andersen, MR Green, ML Rothenberg, MR Modiano, MC Cripps, RK Portenoy, AM Storniolo, P Tarassoff, R Nelson, FA Dorr, CD Stephens, and DD Von Hoff
	JCO Jun 1 1997: 2403–2413. [Abstract] [PDF]
	Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study
	RP Whitehead, J Jacobson, TD Brown, SA Taylor, GR Weiss, and JS Macdonald
	JCO Jun 1 1997: 2414–2419. [Abstract] [PDF]
	Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns
	VE Sutliff, JL Doppman, F Gibril, DJ Venzon, F Yu, J Serrano, and RT Jensen
	JCO Jun 1 1997: 2420–2431. [Abstract] [PDF]
	Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival
	A Zaniboni
	JCO Jun 1 1997: 2432–2441. [Abstract] [PDF]
	Sexual dysfunction in nonseminoma testicular cancer patients is related to chemotherapy-induced angiopathy
	JP van Basten, HJ Hoekstra, MF van Driel, HS Koops, JH Droste, G Jonker-Pool, HB van de Wiel, and DT Sleijfer
	JCO Jun 1 1997: 2442–2448. [Abstract] [PDF]
	Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma
	JA McCaffrey, S Hilton, M Mazumdar, S Sadan, M Heineman, J Hirsch, WK Kelly, HI Scher, and DF Bajorin
	JCO Jun 1 1997: 2449–2455. [Abstract] [PDF]
	Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small- cell lung cancer
	RM Apolinario, P van der Valk, JS de Jong, W Deville, J van Ark-Otte, AM Dingemans, JC van Mourik, PE Postmus, HM Pinedo, and G Giaccone
	JCO Jun 1 1997: 2456–2466. [Abstract] [PDF]
	Double-blind, multicenter, randomized trial to compare the effect of two doses of adrenocorticotropic hormone versus placebo in controlling delayed emesis after high-dose cisplatin in adult patients with cancer
	R Passalacqua, G Cocconi, C Caminiti, V Silingardi, MA Bella, E Bichisao, M Michiara, V Malavasi, D Donati, F Di Costanzo, A Rocca, S Di Sarra, F Scaglione, and F Fraschini
	JCO Jun 1 1997: 2467–2473. [Abstract] [PDF]
Malignancy-associated microangiopathic hemolytic anemia
D Schiller
JCO Jun 1 1997: 2474–2475. [PDF]
Pulmonary changes in patients with lymphoma who receive paclitaxel
JP Ayoub, L North, J Greer, F Cabanillas, and A Younes
JCO Jun 1 1997: 2476a. [PDF]
Changing paradigms in the management of breast cancer
RJ Lee
JCO Jun 1 1997: 2476b–2477. [PDF]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.